股票代码：301047 证券简称：义翘神州 北京义翘神州科技股份有限公司 投资者关系活动记录表 编号：2023-001 | | □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 | | --- | --- | | 投资者关系活动类别 | | | | □新闻发布会 □路演活动 | | | □现场参观 □其他（电话会议、论坛） | | 参与单位名称 | 投资者网上提问 | | 时间 | 年 月 日 (周五) 下午 2023 4 28 15:00-17:00 | | 地点 | 公 司 通 过 全 景 网 投 资 者 关 系 互 动 平 台 " " | | | （https://ir.p5w.net）采用网络远程的方式召开业绩说明会 | | | 董事、总经理、研发总监 张杰 | | 上市公司接待人员 | 董事、财务总监、董事会秘书 冯涛 | | | 独立董事 尹师州 | | | 保荐代表人 赵陆胤 | | | Q1、50 亿理财资金如何用好？ | | | 回复：尊敬的投资者您好，关于资金使用，一方面公司 | | | 将充分保证研发投入及市场拓展需要，支撑公司核心主 | | | 业发展；另一方面，公司也正在积极寻 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥157,085,973.09, a decrease of 10.67% compared to ¥175,846,115.52 in the same period last year[4] - Net profit attributable to shareholders was ¥83,695,323.17, down 26.74% from ¥114,247,512.43 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥49,977,078.41, reflecting a decline of 46.73% from ¥93,809,708.75 in the previous year[4] - Basic earnings per share decreased by 61.44% to ¥0.6478 from ¥1.6801 in the previous year[4] - Total operating revenue for Q1 2023 was ¥157,085,973.09, a decrease of 10.7% from ¥175,846,115.52 in the same period last year[41] - Net profit for Q1 2023 was ¥83,695,323.17, down 26.8% from ¥114,247,512.43 in Q1 2022[42] - Basic earnings per share for Q1 2023 were ¥0.6478, compared to ¥1.6801 in the same period last year[43] - The total comprehensive income for Q1 2023 was ¥81,548,148.47, compared to ¥113,288,428.01 in Q1 2022[43] Cash Flow - The net cash flow from operating activities was ¥33,235,082.48, a significant drop of 51.92% compared to ¥69,121,768.37 in the same quarter last year[4] - The net cash flow from operating activities decreased by 51.92% to ¥33,235,082.48 compared to ¥69,121,768.37 in the previous year, primarily due to increased payments for employee salaries and goods[31] - The net cash flow from investing activities dropped significantly by 114.50% to -¥85,192,213.86 from ¥587,466,728.92 in the previous year, mainly due to cash management and fixed asset purchases[31] - The net cash flow from financing activities improved by 99.20% to -¥5,442,871.92 compared to -¥682,728,089.17 in the previous year, mainly due to cash dividends paid in the previous period[31] - The net cash flow from investing activities was CNY -85.192 million, compared to CNY 587.467 million in the previous year[45] - The net cash flow from financing activities was CNY -5.443 million, compared to CNY -682.728 million in the previous year[45] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,645,508,110.09, an increase of 1.14% from ¥6,570,390,331.09 at the end of the previous year[4] - The total liabilities amounted to ¥193,877,170.53, a decrease from ¥201,007,464.00 in the previous period[20] - The total assets were reported at ¥6,645,508,110.09, slightly down from ¥6,570,390,331.09 in the previous year[20] - The total equity attributable to shareholders increased to ¥6,451,630,939.56 from ¥6,369,382,867.09 in the previous year[20] - The total current assets were reported at ¥6,023,974,157.98, slightly up from ¥5,922,136,726.91 in the previous year[20] - The company’s long-term investments in equity instruments amounted to ¥186,239,867.00, reflecting a stable investment strategy[20] Research and Development - Research and development expenses increased by 113.30% to ¥23,668,344.76, primarily due to the expansion of the R&D team[13] - Research and development expenses for Q1 2023 were ¥23,668,344.76, significantly higher than ¥11,096,271.31 in Q1 2022, indicating increased investment in innovation[41] Government Support and Other Income - The company received government subsidies amounting to ¥2,256,178.76, which included talent project subsidies and other government support[10] - The company reported a significant increase in other income, which rose by 577.28% to ¥2,588,821.76, mainly due to increased government subsidies[13] Market and Business Strategy - The company is exploring market expansion strategies, although specific details were not disclosed in the financial report[39] - The report indicates a focus on regular business growth despite a decline in overall revenue[47] Dividend Distribution - The company plans to distribute a cash dividend of ¥25,840,000 (including tax), amounting to ¥20.00 per 10 shares, pending shareholder approval[37] Miscellaneous - The company has not undergone an audit for the Q1 2023 report[56] - The cash flow from operating activities was not detailed in the provided content but is critical for assessing overall performance[45] - The company experienced a foreign exchange impact of CNY -2.393 million on cash and cash equivalents[45] - Cash and cash equivalents at the end of the period were CNY 2.289 billion, down from CNY 2.837 billion at the end of the previous year[45]

Product Development and Offerings - In 2022, the company launched approximately 1,000 new products, maintaining a core position as a major supplier of infectious disease research reagents with around 68,000 stock products by the end of the year[2]. - The company has developed a product line that includes thousands of biological reagent products, catering to diverse customer research needs[89]. - The company has developed a product library with over 6,500 protein reagent products and approximately 14,000 antibody reagent products, along with around 47,000 gene products[169]. - The company’s recombinant proteins include over 4,500 human cell-expressed products, meeting customer demands for proteins that closely resemble natural human structures and properties[129]. - The company emphasizes the importance of customized services in the biological reagent market, which is expanding due to increasing personalized demands[68]. Financial Performance - The company's operating revenue for 2022 was ¥574,603,390.32, a decrease of 40.47% compared to ¥965,272,540.65 in 2021[56]. - The net profit attributable to shareholders for 2022 was ¥303,134,958.32, down 57.90% from ¥720,013,671.11 in 2021[56]. - The net profit after deducting non-recurring gains and losses was ¥244,352,925.89, a decline of 59.04% compared to ¥596,583,791.15 in the previous year[56]. - The basic earnings per share for 2022 was ¥2.6614, representing a 79.05% decrease from ¥12.7061 in 2021[56]. - The total assets at the end of 2022 were ¥6,570,390,331.09, a decrease of 4.64% from ¥6,890,235,257.55 at the end of 2021[56]. Market Expansion and Strategy - The company signed a lease with Haines Company in November 2022 to establish a new bioresearch center in Houston, Texas, marking a significant step in its global strategic layout[5]. - The company has established subsidiaries in the US, Europe, and Japan, enhancing local service support capabilities[91]. - The company plans to enhance its market position through mergers and acquisitions to increase market concentration in the biological reagent industry[69]. - The company is focused on expanding its market presence through local teams and subsidiaries in key regions[91]. - The company has expanded its market presence in developed countries, establishing subsidiaries in the US, Germany, and Japan to enhance its global footprint[146]. Research and Development - The company plans to continue enhancing its R&D capabilities and expanding its market presence to ensure long-term sustainable development[4]. - The company has a strong R&D team with 44 PhDs, a 19% increase from the previous year, and over 25% of employees holding master's degrees or higher[146]. - The company's overall R&D investment increased by 49.88% year-on-year, enhancing its core competitiveness[168]. - The company emphasizes strong R&D capabilities and rapid response to market demands, exemplified by completing related protein development in just 6 days during the COVID-19 crisis[115]. - The company aims to leverage AI technology and automation in laboratory research to support new product development and enhance its competitive capabilities[186]. Customer Base and Market Demand - The top five customers accounted for CNY 106.94 million in sales, representing 18.61% of the total annual sales, with the largest customer contributing 7.48%[12]. - The company supports over 7,000 clients globally, including universities, research institutions, and pharmaceutical R&D companies, enhancing its brand reputation in the biological reagent industry[103]. - The demand for customized products and services has increased, prompting the company to strengthen local logistics and customer service teams[90]. - The bioreagent and technical service market is characterized by diverse customer needs and a lack of unified quality standards, which the company aims to address[89]. - The company is actively expanding its service business and improving customer satisfaction, leading to a continuous increase in market share and revenue growth[4]. Operational Challenges and Adjustments - The company's unconventional business related to COVID-19 saw a significant decline of 73.19% year-on-year, prompting a strategic business adjustment[187]. - The fourth quarter net profit was significantly impacted by fluctuations in the financial market, particularly due to changes in the fair value of financial products[59]. - Direct labor costs increased by 66.20% to ¥38,390,531.54, making up 44.62% of total operating costs[194]. - Material costs rose by 16.78% to ¥28,843,653.21, accounting for 33.52% of total operating costs[194]. - The company has established a strict quality assessment and control standard for its biological reagent products, ensuring compliance with various operational procedures[135]. Government Support and Subsidies - The company reported government subsidies of CNY 14.78 million in 2022, a decrease from CNY 67.11 million in 2021[22]. - The company has achieved ISO9001, ISO13485, and CNAS certifications, and its purification workshop has passed GMP compliance certification[191]. - The company has established a comprehensive quality management system certified by ISO9001, ISO13485, and CNAS, ensuring product quality throughout its lifecycle[158].

证券代码：301047 证券简称：义翘神州 公告编号：2023-031 北京义翘神州科技股份有限公司 关于举行 2022 年度网上业绩说明会的公告 1 一、召开时间及方式 1、召开时间：2023 年 4 月 28 日（星期五）下午 15:00-17:00 2、召开方式：本次年度业绩说明会将采用网络远程的方式举行，投资者可 在上述时间登陆全景网"投资者关系互动平台"（http://ir.p5w.net）参与本次年 度业绩说明会。 二、公司出席人员 公司董事兼总经理兼研发总监张杰先生、董事兼董事会秘书兼财务总监冯涛 先生、独立董事尹师州先生、保荐代表人赵陆胤女士。 三、投资者问题征集方式 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可提前访问 http://ir.p5w.net/zj/，或扫描下方二维码，进入问题征集专题页面进行提问。公司 将在 2022 年度业绩说明会上，对投资者普遍关注的问题进行回答。 欢迎广大投资者积极参与！ 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 ...

股票代码：301047 证券简称：义翘神州 北京义翘神州科技股份有限公司 投资者关系活动记录表 编号：- | --- | --- | --- | |--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

股票代码：301047 证券简称：义翘神州 北京义翘神州科技股份有限公司 投资者关系活动记录表 编号：2021-002 | --- | --- | --- | |--------------------|-------------------------------------------------------------------------------------------|--------------------| | | | | | | √特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | | 投资者关系活动类别 | □新闻发布会 □路演活动 | | | | □现场参观 √其他（电话会议、论坛） | | | | 刘奎 北京屹唐赛盈基金管理有限公司；杨磊 | 博时基金管 | | | 理有限公司；吴博文 淡水泉投资管理有限公司；吴佳歆、 | | | | 毛可君 东吴基金管理有限公司；华如嫣 | 歌斐资产管理有 | | | 限公司；劳亭嘉 工银安盛人寿资管；夏芳芳 | 国华人寿保 | | | 险股份有限公司；朱娉洁 国泰君安证券股份有限公司； | | | | 李子波 国泰君安 ...

股票代码：301047 证券简称：义翘神州 北京义翘神州科技股份有限公司 投资者关系活动记录表（更正版） 编号：2022-005 | --- | --- | --- | --- | --- | --- | |--------------------|----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------- ...

股票代码：301047 证券简称：义翘神州 北京义翘神州科技股份有限公司 投资者关系活动记录表 编号：2022-004 | --- | --- | --- | --- | |--------------------|----------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

股票代码：301047 证券简称：义翘神州 北京义翘神州科技股份有限公司 投资者关系活动记录表 编号：- | --- | --- | --- | --- | |--------------------|---------------------------------------------------------------------------------------------------------------|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | ...

Financial Performance - The company's revenue for Q3 2022 was ¥130,983,535.64, a decrease of 26.52% compared to the same period last year[6]. - The net profit attributable to shareholders was ¥83,705,363.76, down 26.39% year-on-year[6]. - The net profit excluding non-recurring gains and losses was ¥41,058,539.50, reflecting a significant decline of 58.31% compared to the previous year[6]. - The company's basic earnings per share were ¥0.6479, down 67.71% year-on-year[6]. - In the first three quarters of 2022, the company achieved operating revenue of 430 million RMB, a year-on-year decrease of 47.07%[27]. - In Q3 2022, the company achieved revenue of 131 million yuan, a year-over-year decrease of 26.52%, but a quarter-over-quarter increase of 6.10%[28]. - Revenue from non-COVID-19 related business was 111 million yuan, showing a year-over-year growth of 18.06% and a quarter-over-quarter growth of 13.20%[28]. - Total operating revenue for the current period is CNY 430,286,790.03, a decrease from CNY 812,948,531.27 in the previous period, representing a decline of approximately 47%[40]. - Net profit for the current period is CNY 275,901,898.54, down from CNY 556,362,582.99 in the previous period, indicating a decrease of approximately 51%[43]. - Operating profit decreased to CNY 322,168,393.07 from CNY 658,413,618.40, reflecting a decline of around 51%[43]. - The basic earnings per share for the current period is CNY 2.5359, compared to CNY 10.5195 in the previous period, a decline of approximately 76%[43]. Assets and Liabilities - Total assets at the end of the reporting period were ¥6,511,465,199.82, a decrease of 5.50% from the end of the previous year[6]. - As of September 30, 2022, the company's total assets amounted to 6.51 billion yuan, down from 6.89 billion yuan at the beginning of the year[33]. - The company's cash and cash equivalents were approximately 2.37 billion yuan, a decrease from 2.87 billion yuan at the start of the year[33]. - The total liabilities of the company as of September 30, 2022, were 170.83 million yuan, compared to 137.92 million yuan at the beginning of the year[36]. - The company's total equity attributable to shareholders was approximately 6.34 billion yuan, down from 6.75 billion yuan at the beginning of the year[39]. Cash Flow - The cash flow from operating activities for the year-to-date was ¥169,882,187.35, a decrease of 62.73% compared to the same period last year[14]. - Operating cash inflow totaled ¥502,400,622.79, a decrease of 42.4% from ¥872,847,387.20 in the previous period[47]. - Net cash outflow from operating activities was ¥169,882,187.35, down from ¥455,852,218.88, indicating a significant decline[47]. - Cash inflow from investment activities was ¥10,639,688,833.56, compared to ¥2,545,611,806.61 in the prior period, showing a substantial increase[50]. - Cash outflow from financing activities amounted to ¥693,261,769.57, while the previous period recorded inflow of ¥4,720,050,530.28, indicating a shift in financing strategy[50]. - The ending balance of cash and cash equivalents was ¥2,325,314,658.30, down from ¥4,654,977,849.90, indicating a liquidity contraction[50]. Inventory and Fixed Assets - Inventory increased by 67.27% to ¥41,401,459.95, primarily due to increased raw material reserves[11]. - Fixed assets rose by 75.98% to ¥104,549,193.03, mainly due to the purchase of production and R&D equipment[11]. - The company reported an increase in inventory to approximately 41.40 million yuan, up from 24.75 million yuan at the beginning of the year[33]. Research and Development - The company maintained its position as a mainstream supplier of COVID-19 related biological reagents, leveraging its extensive R&D experience in the field[27]. - The company increased its R&D investment in non-COVID-19 related business, resulting in a 30.52% year-on-year increase in CRO service revenue, totaling 76.81 million RMB[27]. - The company’s strategic focus on enhancing long-term competitiveness through increased R&D investment in non-COVID-19 related business is evident[27]. - Research and development expenses for the current period are CNY 39,332,093.12, up from CNY 32,116,971.18, indicating an increase of approximately 22%[40]. Government Support and Other Income - The company received government subsidies amounting to ¥13,363,773.64 during the reporting period[9]. - Other income increased to CNY 13,924,074.09 from CNY 3,353,594.12, reflecting a growth of about 316%[40]. - The company reported a tax expense of CNY 46,290,442.18, down from CNY 101,551,035.41, indicating a decrease of approximately 54%[43]. Subsidiary Developments - The Suzhou subsidiary has completed renovation acceptance and is currently in the laboratory equipment debugging phase[32]. - The Taizhou subsidiary has completed the main renovation work of the first phase of the laboratory and has begun trial operations[32]. - The company has ongoing projects in Suzhou and Taizhou, indicating a focus on market expansion and new technology development[32].